8-K: Avenue Therapeutics Terminates License Agreement with AnnJi Pharmaceutical, Transfers Assets

Avenue Therapeutics and AnnJi Pharmaceutical have terminated their license agreement, with Avenue transferring rights to AJ201 back to AnnJi and receiving potential milestone payments and royalties.

Summary

• Avenue Therapeutics, Inc. and AnnJi Pharmaceutical Co., Ltd. have entered into a License Termination and Program Transfer Agreement, effective April 24, 2025.
• The agreement terminates the original License Agreement from February 28, 2023, under which Avenue had licensed intellectual property rights to the molecule JM17 (underlying AJ201) from AnnJi.
• Avenue will transfer all rights to assets related to AJ201 back to AnnJi.
• Avenue has agreed not to compete with AJ201 in the US, Canada, the European Union, Great Britain, or Israel for 48 months.
• AnnJi will repurchase 14,777 shares of Avenue common stock for $1.00 and pay Avenue $0.2 million for legal expenses.
• AnnJi will pay Avenue $2.0 million over the next 90 days ($1.0 million within 30 days and $1.0 million within 90 days of the effective date).
• Avenue is eligible for up to $5 million in development and regulatory milestone payments, up to $17 million in commercial sales milestone payments, and a 1.75% royalty on net sales of AJ201.
• Avenue could receive 15% of payments from AnnJi's subsequent licenses of AJ201, up to $7.5 million, with a minimum of $4 million under certain conditions related to U.S. approval.
• All pending dispute resolution proceedings are dismissed, and mutual releases of claims are provided.
• Since March 19, 2025, Avenue's common stock has been traded on the over-the-counter market under the symbol ATXI after being delisted from the Nasdaq.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While Avenue receives some payments and potential future revenue, it loses control of a key asset and faces a non-compete restriction. The delisting from Nasdaq is also a negative factor.

Positives

• Avenue will receive $2.0 million from AnnJi within 90 days.
• Avenue is eligible for up to $5 million in development and regulatory milestones.
• Avenue is eligible for up to $17 million in commercial sales milestones.
• Avenue will receive a 1.75% royalty on net sales of AJ201.
• Avenue could receive 15% of payments from AnnJi's subsequent licenses of AJ201, up to $7.5 million, with a minimum of $4 million under certain conditions related to U.S. approval.
• AnnJi will repurchase 14,777 shares of Avenue common stock for $1.00.
• Avenue will receive $0.2 million for legal expenses.

Negatives

• Avenue is transferring all rights to AJ201 back to AnnJi, relinquishing control over its development and commercialization.
• Avenue has agreed not to compete with AJ201 for 48 months in key markets, limiting its strategic options.
• Avenue's common stock has been traded on the over-the-counter market under the symbol ATXI after being delisted from the Nasdaq.

Risks

• The potential milestone and royalty payments are contingent on AnnJi's success in developing and commercializing AJ201.
• There is no guarantee that AnnJi will achieve the development, regulatory, or commercial milestones necessary for Avenue to receive these payments.
• The 1.75% royalty on net sales of AJ201 is subject to potential diminution in certain circumstances.
• Avenue's agreement not to compete with AJ201 for 48 months could limit its ability to pursue alternative opportunities in the same therapeutic area.
• The delisting from Nasdaq could affect investor confidence and access to capital.

Future Outlook

Avenue's future financial performance is now heavily reliant on AnnJi's success with AJ201 and the achievement of specific milestones and sales targets. Avenue will need to explore alternative strategies given the non-compete agreement.

Industry Context

This agreement reflects a strategic shift for Avenue Therapeutics, moving away from direct development of AJ201 and relying on AnnJi for its future success. This type of agreement is common in the pharmaceutical industry, where companies may choose to out-license assets to partners with more resources or expertise in a particular area.

Comparison to Industry Standards

• License termination agreements are common in the pharmaceutical industry when partnerships no longer align with strategic goals.
• Milestone payments and royalties are standard components of licensing agreements, providing the original licensor with a continued stake in the success of the asset.
• The specific royalty rate of 1.75% is relatively low compared to some industry standards, which can range from single digits to the low teens, but this depends on the stage of development and the perceived value of the asset.
• The non-compete clause is a typical provision to protect the licensee's investment in the asset.

Legal Proceedings

• All pending dispute resolution proceedings between Avenue and AnnJi are dismissed.

Related Party Transactions

• AnnJi will repurchase 14,777 shares of Avenue common stock for $1.00.

Stakeholder Impact

• Shareholders: The impact is mixed, with potential for future revenue but loss of control over a key asset and delisting from Nasdaq.
• Employees: Potential impact on employees involved in the AJ201 program.
• Customers: No immediate impact on customers, as AJ201 is still in development.
• Suppliers: Potential impact on suppliers involved in the AJ201 program.

Next Steps

• AnnJi will proceed with the development and commercialization of AJ201.
• Avenue will monitor AnnJi's progress and seek to achieve the milestone and royalty payments outlined in the agreement.
• Avenue will need to develop a new strategic plan given the loss of the AJ201 asset and the non-compete agreement.

Key Dates

Keywords

License Termination, Program Transfer, AJ201, JM17, AnnJi Pharmaceutical, Avenue Therapeutics, Milestone Payments, Royalties, Competition, Delisting